3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Pancreatic Neoplasms
6
Prostatic Neoplasms
3
Multiple Myeloma
3
Colorectal Neoplasms
3
Unspecified Adult Solid Tumor, Protocol Specific
2
Rectal Neoplasms
2
Neoplasms, Plasma Cell
2
Neoplasms
2
Melanoma
2
Glioblastoma
2
Colonic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Adenocarcinoma
2
Solid Tumor
1
Sarcoma, Clear Cell
1
Refractory or Relapsed Solid Tumors
1
Platinum-resistant Epithelial Ovarian Cancer
1
Neoplasm Metastasis
1
Malignant Solid Tumour
1
Lymphangioleiomyomatosis
1
Lung Neoplasms
1
Liver Neoplasms
1
Klatskin Tumor
1
Gliosarcoma
1
Gastrointestinal Neoplasms
1
Cholangiocarcinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Arthritis, Rheumatoid
1
Anatomic Stage I Breast Cancer AJCC v8
1
Interventions
Sirolimus
6
Everolimus
5
saracatinib
1
nintedanib
1
Urination
1
Sugars
1
Simvastatin
1
Resveratrol
1
Octreotide
1
Letrozole
1
Imatinib Mesylate
1
Hydroxychloroquine
1
Glutamine
1
Doxycycline
1
Celecoxib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Lymphangioleiomyomatosis
×
Hydroxychloroquine
×
Clear all
NCT01687179
2018-10-11
SAIL
Brigham and Women's Hospital
Phase 1
Completed
14 enrolled
14 charts